Ars Pharmaceuticals, Inc. · NASDAQ:SPRY
Ars Pharmaceuticals — 43rd Annual J.P. Morgan Healthcare Conference 2025
15 slides from Ars Pharmaceuticals's conference presentation, Jan 13, 2025
Slide 1: 43rd Annual J.P. Morgan Healthcare Conference January 2025
43rd Annual J.P. Morgan Healthcare Conference January 2025 neffy – the transformative needle-free solution for severe allergic reactions NASDAQ: SPRY Exhibit 99.2
Slide 2: Forward-looking statements
Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements reg
Slide 3: Transforming the Treatment of Type I Allergic Reactions
Transforming the Treatment of Type I Allergic Reactions neffy®: first and only FDA and EC approved “no needle, no injection” solution for Type I allergic reactions Strong execution during first 3 months of launch in Q4 2024 sets foundation for delivering significant neffy US sales in 2025 Prescribin
Slide 4: Type I Allergy Patients Face Significant Limitations with Other Treatment Options
Type I Allergy Patients Face Significant Limitations with Other Treatment Options that neffy may help to address References: 1. Warren CM, et al. Ann Allergy Asthma Immunol. 2018. 2. Rooney E, et al. Poster Presentation at ACAAI 2022 (Louisville, KY). 3. Brooks C, et al. Ann Allergy Asthma Immunol.
Slide 5: Addressing the Significant Unmet Needs in US Severe Allergic Reaction Patient Population
Addressing the Significant Unmet Needs in US Severe Allergic Reaction Patient Population References: 1. Based on IQVIA prescription data available through 2023 (~5.2 million two-packs sold in 2023). 2. Gupta RS, et al. Pediatrics. 2011. 3. Gupta RS, et al. Pediatrics 2018. 4. McGowan EC, et al. J Cl
Slide 6: Ex-US partners enable ARS to focus exclusively on the United States
Ex-US partners enable ARS to focus exclusively on the United States References: 1. 2023 IQVIA data based on estimated gross-to-net for generic and branded autoinjector products in the United States, 2. ALK Press Release (Nov 9, 2024) ALK licenses rights to neffy®, the first approved adrenaline nasal
Slide 7: Commercialization Progress
Commercialization Progress ARS Pharmaceuticals, Inc. Investor Presentation – January 2025
Slide 8: Strategic Objectives for Commercialization
ACTIVATE PATIENTS Accelerated DTC campaign prior to end of school year to increase awareness and motivate patients and caregivers to seek neffy REACH MORE PRESCRIBERS Option to expand CME, direct HCP marketing and sales force to drive prescriber uptake FACILITATE ACCESS Obtain 60%, growing to 80%+ c
Slide 9: neffy: Delivering on Expectations
neffy: Delivering on Expectations $7.1 million in preliminary net product sales Thirteen weeks post launch (ending Dec. 31, 2024) ARS Pharmaceuticals, Inc. Investor Presentation – January 2025 $4.1 million in consensus net product sales Analyst estimates for FY20241 $3.4 million Internal forecast ne
Slide 10: EDUCATE: Enable real-world experience with neffy
EDUCATE Enable real-world experience with neffy Target allergist offices that conduct in-office food challenge testing HCPs will have the ability to gain first-hand knowledge of neffy’s effectiveness Patients undergoing allergy challenge will also be exposed to neffy 1,750+ HCPs and growing have enr
Slide 11: On track to ensuring broad neffy access for patients
On track to ensuring broad neffy access for patients FACILITATE ARS Pharmaceuticals, Inc. Investor Presentation – January 2025 Contract discussions with key payers on track for commercial coverage targets >60%+ coverage anticipated by 6 months post-launch (end of Q1 2025) >80%+ coverage anticipated
Slide 12: Plans to increase awareness & motivation to seek and prescribe neffy
Plans to increase awareness & motivation to seek and prescribe neffy as access expands in 2025 ACTIVATE Consumer Marketing Activities ARS Pharmaceuticals, Inc. Investor Presentation – January 2025 Branded neffy DTC Campaign starting in Q2 2025 with celebrity spokesperson later in 2025 Expand Direct
Slide 13: Targeted Healthcare Providers Indicate Significant Uptake in 2025
Targeted Healthcare Providers Indicate Significant Uptake in 2025 December 2024 Survey1, Sample = 150 HCPs from our 12,500 targets ~ 40-45% of epi Rx References: 1. HCP Market Research Study, December 2024 ARS Pharmaceuticals, Inc. Investor Presentation – January 2025 % of target prescribers for who
Slide 14: Treatment of acute flares in chronic spontaneous urticaria represents blockbuster opportunity
Treatment of acute flares in chronic spontaneous urticaria patients on antihistamines represents blockbuster opportunity ~2M diagnosed chronic urticaria patients based on 12 month US prevalence of 0.78%1 ~1M US chronic urticaria patients reported to be treated with Rx medication1 ~8-9 HCP visits per
Slide 15: A Path to Blockbuster Potential for neffy
A Path to Blockbuster Potential for neffy Q4 2024 2025 2026 Multi-blockbuster peak sales potential driven by initial $3B segment, ~$7B expansion segment and ~$2-3B+ CSU indication Broad commercial coverage with 80%+ targeted by end of Q3 ‘25 Accelerated activation of consumer awareness with branded
ARS Pharmaceuticals — 43rd Annual J.P. Morgan Healthcare Conference 2025 on 6ix